California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Population Informatics Lab, School of Public Health, Texas A&M University, College Station, TX, USA.
Clin Mol Hepatol. 2023 Apr;29(2):453-464. doi: 10.3350/cmh.2022.0450. Epub 2023 Feb 1.
BACKGROUND/AIMS: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is often asymptomatic and can go undiagnosed for years, leading to underuse of HCC surveillance in clinical practice. We characterized the frequency and associated factors of unrecognized cirrhosis in a national sample of patients with HCC from the United States.
HCC patients aged 68 years and older, diagnosed during 2011 to 2015 were included from the SEERMedicare Linked Database. If cirrhosis was diagnosed within 6 months immediately preceding HCC diagnosis or after HCC diagnosis, cases were categorized as unrecognized cirrhosis. Factors associated with unrecognized cirrhosis were identified using logistic regression analyses. Factors associated with overall survival were evaluated using Cox regression analyses.
Among 5,098 HCC patients, 74.8% patients had cirrhosis. Among those with cirrhosis, 57.4% had unrecognized cirrhosis, with the highest proportion (76.3%) among those with NAFLD-related HCC. Male sex (aOR: 2.12, 95% CI: 1.83-2.46), non-Hispanic Black race (aOR: 1.93, 95% CI: 1.45-2.57), and NAFLD etiology (aOR: 4.46, 95% CI: 3.68-5.41) were associated with having unrecognized cirrhosis. Among NAFLD-related HCC patients, male sex (aOR: 2.32, 95% CI: 1.71-3.14) was associated with unrecognized cirrhosis. Unrecognized cirrhosis was independently associated with worse overall survival (aHR: 1.17, 95% CI: 1.08-1.27) compared to recognized cirrhosis.
Unrecognized cirrhosis is common in NAFLD-related HCC, particularly among male and Black patients, highlighting these groups as important intervention targets to improve HCC surveillance uptake and outcomes.
背景/目的:肝硬化是肝细胞癌(HCC)最重要的危险因素,建议肝硬化患者每半年进行一次 HCC 早期检测的监测。然而,早期肝硬化通常没有症状,可能多年未被诊断,导致 HCC 监测在临床实践中的使用率不足。我们在美国的一项 HCC 患者全国样本中描述了未被识别的肝硬化的频率和相关因素。
纳入了 2011 年至 2015 年期间从 SEER-Medicare 关联数据库中诊断的年龄在 68 岁及以上的 HCC 患者。如果肝硬化是在 HCC 诊断前 6 个月内或 HCC 诊断后即刻诊断出的,则将病例归类为未被识别的肝硬化。使用逻辑回归分析确定与未被识别的肝硬化相关的因素。使用 Cox 回归分析评估与总生存相关的因素。
在 5098 例 HCC 患者中,74.8%的患者有肝硬化。在有肝硬化的患者中,57.4%的患者有未被识别的肝硬化,其中非酒精性脂肪性肝病相关 HCC 的比例最高(76.3%)。男性(优势比[OR]:2.12,95%可信区间[CI]:1.83-2.46)、非西班牙裔黑人种族(OR:1.93,95%CI:1.45-2.57)和非酒精性脂肪性肝病病因(OR:4.46,95%CI:3.68-5.41)与未被识别的肝硬化有关。在非酒精性脂肪性肝病相关 HCC 患者中,男性(OR:2.32,95%CI:1.71-3.14)与未被识别的肝硬化有关。与已识别的肝硬化相比,未被识别的肝硬化与总生存较差独立相关(风险比[aHR]:1.17,95%CI:1.08-1.27)。
未被识别的肝硬化在非酒精性脂肪性肝病相关 HCC 中很常见,尤其是在男性和黑人患者中,这突出了这些群体作为提高 HCC 监测接受度和结果的重要干预目标。